CLPT Stock Price, ClearPoint Neuro Inc Quote, Chart

Market Summary

USD5.52+0.10

Market Closed

1.85%

CLPT Stock Price

View Fullscreen

CLPT RSI Chart

CLPT Valuation

Market Cap

148.9M

Price/Earnings (Trailing)

-6.74

Price/Sales (Trailing)

6.22

Price/Free Cashflow

-10.31

CLPT Price/Sales (Trailing)

CLPT Profitability

Operating Margin

56.83%

Return on Equity

-104.33%

Return on Assets

-51.78%

Free Cashflow Yield

-9.7%

CLPT Fundamentals

CLPT Revenue

Revenue (TTM)

24.0M

Rev. Growth (Yr)

31.62%

Rev. Growth (Qtr)

18.19%

CLPT Earnings

Earnings (TTM)

-22.1M

Earnings Growth (Yr)

-5.34%

Earnings Growth (Qtr)

3.95%

Breaking Down CLPT Revenue

Last 7 days

4.0%

Last 30 days

-14.4%

Last 90 days

-22.8%

Trailing 12 Months

-40.9%

How does CLPT drawdown profile look like?

CLPT Financial Health

Current Ratio

4.87

Debt/Equity

0.47

Debt/Cashflow

-1.38

CLPT Investor Care

Shares Dilution (1Y)

0.27%

Diluted EPS (TTM)

-0.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	21.0M	21.7M	22.3M	24.0M
2022	17.3M	19.1M	19.7M	20.6M
2021	13.7M	14.7M	15.7M	16.3M
2020	11.9M	11.7M	12.3M	12.8M
2019	8.2M	9.2M	10.3M	11.2M
2018	7.0M	6.7M	6.8M	7.4M
2017	6.4M	7.2M	7.3M	7.4M
2016	3.7M	4.4M	5.1M	5.7M
2015	2.8M	1.7M	2.3M	3.0M
2014	3.5M	4.1M	3.8M	2.6M
2013	5.3M	4.8M	4.6M	3.9M
2012	4.0M	4.4M	4.4M	5.1M
2011	3.0M	3.2M	3.5M	3.8M
2010	0	0	0	2.7M
2009	0	0	0	2.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ClearPoint Neuro Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	richards timothy t.	acquired	11,152	6.8	1,640	-
Apr 01, 2024	liau linda m.	acquired	2,964	6.8	436	-
Apr 01, 2024	girin pascal e r	acquired	7,180	6.8	1,056	-
Apr 01, 2024	fletcher r john	acquired	5,780	6.8	850	-
Mar 06, 2024	sabra mazin	acquired	-	-	6,913	chief operating officer
Mar 06, 2024	stigall l. jeremy	sold (taxes)	-19,843	6.24	-3,180	chief business officer
Mar 06, 2024	d'alessandro danilo	sold (taxes)	-29,440	6.24	-4,718	chief financial officer
Mar 06, 2024	d'alessandro danilo	acquired	-	-	9,383	chief financial officer
Mar 06, 2024	sabra mazin	sold (taxes)	-21,609	6.24	-3,463	chief operating officer
Mar 06, 2024	burnett joseph michael	acquired	-	-	23,704	ceo and president

Which funds bought or sold CLPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Key Financial Inc	unchanged	-	-	170	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	sold off	-100	-90,837	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	27.00	27.00	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	added	8.19	34,000	436,000	-%
Apr 26, 2024	JAMISON PRIVATE WEALTH MANAGEMENT, INC.	unchanged	-	3.00	2,040	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-10.2	-42,410	378,685	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-	442	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-56.45	-8,000	5,000	-%
Apr 24, 2024	BROWN ADVISORY INC	unchanged	-	3,334	2,267,090	-%

Are Funds Buying or Selling CLPT?

Are funds buying CLPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLPT

No. of Funds

Unveiling ClearPoint Neuro Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.32%	1,308,694	SC 13G
Feb 06, 2024	bigger capital, llc	3.5%	868,042	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	1,470,056	SC 13G
Jun 15, 2023	ptc therapeutics, inc.	9.76%	2,561,245	SC 13D/A
Feb 09, 2023	bigger capital fund l p	3.0%	746,994	SC 13G/A
Jan 26, 2022	bigger capital fund l p	2.8%	655,690	SC 13G/A
Jun 09, 2021	bigger capital fund l p	2.8%	575,484	SC 13G
Mar 02, 2021	ptc therapeutics, inc.	14.00%	2,961,245	SC 13D/A
Feb 11, 2021	satterfield thomas a jr	4.0%	720,000	SC 13G/A
Feb 13, 2020	satterfield thomas a jr	7.8%	1,225,000	SC 13G/A

Recent SEC filings of ClearPoint Neuro Inc

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	DEF 14A	DEF 14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 12, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to ClearPoint Neuro Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.3B	40.3B	-5.44%	-5.22%	32.76	4.57	-2.84%	-3.08%
BDX	69.5B	19.7B	-0.20%	-8.75%	52.15	3.53	4.82%	-17.56%
ALGN	21.5B	3.9B	-8.18%	-5.47%	48.35	5.57	3.42%	23.09%
BAX	18.8B	14.9B	-13.96%	-20.60%	7.1	1.26	2.98%	207.68%
MID-CAP
ATR	9.7B	3.5B	3.73%	21.66%	30.9	2.73	6.16%	35.06%
HSIC	8.8B	12.3B	-6.12%	-14.26%	21.19	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-15.06%	-39.81%	-12.8	3.05	-4.68%	82.43%
XRAY	5.9B	3.9B	-10.84%	-29.89%	-63.02	1.5	0.23%	91.03%
AXNX	3.4B	387.1M	-2.63%	29.53%	-215.05	8.84	30.82%	65.60%
PDCO	2.3B	6.6B	-3.75%	-4.94%	11.77	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	-4.08%	-10.47%	-2.03	0.43	7.73%	-1066.14%
ANIK	409.1M	166.7M	6.81%	6.12%	-4.95	2.45	6.67%	-456.34%
ANGO	243.5M	324.0M	-1.78%	-29.87%	-1.27	0.75	-3.19%	-337.41%
APYX	49.5M	52.3M	-3.38%	-60.28%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-22.16%	302.94%	-0.29	0.96	5.77%	8.23%

ClearPoint Neuro Inc News

Latest updates

ClearPoint Neuro Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	18.2%	6,810	5,762	5,950	5,433	5,174	5,146	5,200	5,031	4,282	4,574	3,413	4,030	3,716	3,519	2,478	3,116	3,211	2,927	2,606	2,473	2,277
Cost Of Revenue	12.4%	2,797	2,489	2,824	2,231	1,808	1,467	1,945	1,800	1,093	1,533	1,139	1,416	1,073	903	802	932	1,042	983	1,030	886	689
Gross Profit	22.6%	4,013	3,273	3,126	3,202	3,366	3,679	3,255	3,231	3,189	3,041	2,274	2,614	-	2,616	1,676	-	-	-	-	-	-
S&GA Expenses	-6.2%	2,720	2,900	3,178	2,958	2,376	2,398	2,661	2,176	1,931	2,436	1,982	1,657	1,528	1,252	1,214	1,276	1,312	1,030	1,028	933	1,206
R&D Expenses	9.2%	2,652	2,429	3,605	3,023	2,928	2,654	2,411	2,901	3,041	2,601	2,109	1,563	1,913	1,143	812	818	766	762	698	585	481
Interest Expenses	-9.0%	91.00	100	81.00	114	84.00	32.00	-91.00	-106	1,211	-238	240	332	204	201	197	842	229	213	259	254	238
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	4.0%	-4,619	-4,809	-7,052	-5,609	-4,385	-3,788	-4,303	-3,959	-4,149	-3,980	-3,743	-2,538	-1,582	-1,484	-1,661	-2,055	-1,645	-1,122	-1,550	-1,220	-1,217
Net Income Margin	5.8%	-0.92*	-0.98*	-0.96*	-0.86*	-0.80*	-0.82*	-0.86*	-0.92*	-0.88*	-0.75*	-0.64*	-0.53*	-	-	-	-	-	-	-	-	-
Free Cashflow	45.1%	-1,141	-2,080	-5,423	-5,838	-3,137	-3,921	-5,057	-4,338	-3,590	-3,421	-3,683	-2,171	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-2.7%	43.00	44.00	48.00	50.00	55.00	58.00	60.00	62.00	66.00	69.00	72.00	74.00	30.00	22.00	23.00	24.00	12.00	13.00	13.00	8.00	8.00
Current Assets	-3.1%	36.00	37.00	41.00	46.00	51.00	54.00	57.00	58.00	62.00	65.00	69.00	70.00	25.00	20.00	21.00	22.00	10.00	12.00	12.00	6.00	7.00
Cash Equivalents	-4.8%	23.00	24.00	27.00	22.00	28.00	19.00	24.00	50.00	54.00	58.00	62.00	65.00	20.00	15.00	16.00	17.00	6.00	6.00	7.00	2.00	3.00
Inventory	-12.0%	8.00	9.00	9.00	10.00	9.00	8.00	7.00	6.00	5.00	4.00	4.00	3.00	3.00	4.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00
Net PPE	2.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	8.8%	21.00	20.00	20.00	18.00	19.00	18.00	17.00	16.00	17.00	25.00	24.00	30.00	27.00	22.00	22.00	21.00	7.00	7.00	6.00	7.00	6.00
Current Liabilities	32.9%	7.00	6.00	6.00	6.00	7.00	6.00	5.00	4.00	5.00	5.00	4.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	3.00	2.00	2.00
Long Term Debt	-	10.00	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	-	-	-	-	-	-
Shareholder's Equity	-12.1%	21.00	24.00	27.00	33.00	37.00	40.00	43.00	46.00	49.00	44.00	48.00	44.00	2.00	0.00	1.00	3.00	5.00	6.00	7.00	0.00	2.00
Retained Earnings	-2.5%	-172	-167	-163	-156	-150	-145	-142	-137	-133	-130	-126	-122	-119	-117	-116	-114	-112	-111	-109	-108	-107
Additional Paid-In Capital	0.9%	193	192	190	188	187	186	185	183	182	174	174	166	122	118	118	117	117	117	117	109	109
Shares Outstanding	0.1%	25.00	25.00	25.00	25.00	25.00	24.00	24.00	24.00	24.00	21.00	22.00	19.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	155	-	-	-	272	-	-	-	361	-	-	-	43.00	-	-	-	43.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	39.3%	-1,120	-1,845	-5,075	-5,680	-3,065	-3,852	-4,981	-4,269	-3,552	-3,296	-3,718	-2,131	-2,401	-1,367	-1,708	-2,331	-466	-964	-810	-609	-582
Share Based Compensation	-2.6%	1,543	1,584	1,645	1,307	1,172	1,175	880	899	925	586	247	320	328	293	241	228	223	219	204	153	378
Cashflow From Investing	20.0%	-188	-235	9,510	-138	11,746	-631	-21,666	-185	-38.00	-125	35.00	-40.00	-41.00	-	-	-441	190*	-10.19	-	-	-839*
Cashflow From Financing	270.3%	155	-91.00	237	-5.00	222	-329	513	3.00	48.00	-452	349	46,930	7,876	-	764	14,052	-72.93	-252	-	-	-26.59

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLPT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 23,955	$ 20,551
Cost of revenue	10,341	7,020
Gross profit	13,614	13,531
Research and development costs	11,709	10,894
Sales and marketing expenses	12,595	9,358
General and administrative expenses	11,756	9,611
Operating loss	(22,446)	(16,332)
Other income (expense):
Other expense, net	(29)	(22)
Interest income (expense), net	386	(81)
Net loss	$ (22,089)	$ (16,435)
Net loss per share attributable to common stockholders:
Basic (in usd per share)	$ (0.90)	$ (0.68)
Diluted (in usd per share)	$ (0.90)	$ (0.68)
Weighted average shares outstanding:
Basic (in shares)	24,605,212	24,181,854
Diluted (in shares)	24,605,212	24,181,854
Product revenue
Revenue:
Total revenue	$ 10,603	$ 12,789
Service and other revenue
Revenue:
Total revenue	$ 13,352	$ 7,762

CLPT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,140	$ 27,615
Short-term investments	0	9,874
Accounts receivable, net	3,211	2,665
Inventory, net	7,911	9,303
Prepaid expenses and other current assets	1,910	1,723
Total current assets	36,172	51,180
Property and equipment, net	1,389	806
Operating lease rights of use	3,564	1,895
Software license inventory	386	450
Licensing rights	1,041	1,028
Other assets	109	131
Total assets	42,661	55,490
Current liabilities:
Accounts payable	393	272
Accrued compensation	2,947	2,824
Other accrued liabilities	1,053	2,065
Operating lease liabilities, current portion	424	561
Deferred product and service revenue, current portion	2,613	1,066
Total current liabilities	7,430	6,788
Operating lease liabilities, net of current portion	3,568	1,532
Deferred product and service revenue, net of current portion	541	390
2020 senior secured convertible note payable, net	9,949	9,893
Total liabilities	21,488	18,603
Commitments and contingencies (Note 8)
Stockholders' Equity Attributable to Parent [Abstract]
Preferred stock, $0.01 par value; 25,000,000 shares authorized at December 31, 2023 and 2022; none issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.01 par value; 90,000,000 shares authorized at December 31, 2023 and 200,000,000 shares authorized at December 31, 2022; 24,652,729 and 24,578,983 shares issued and outstanding at December 31, 2023 and 2022, respectively	247	246
Additional paid-in capital	193,382	187,008
Accumulated deficit	(172,456)	(150,367)
Total stockholders’ equity	21,173	36,887
Total liabilities and stockholders’ equity	$ 42,661	$ 55,490
Common stock, authorized (in shares)	90,000,000	200,000,000

About ClearPoint Neuro Inc

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain. It has license and collaboration agreements with Clinical Laserthermia Systems AB, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

CEO	Mr. Joseph Michael Burnett
WEBSITE	clearpointneuro.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	108

ClearPoint Neuro Inc Frequently Asked Questions

What is the ticker symbol for ClearPoint Neuro Inc? What does CLPT stand for in stocks?

CLPT is the stock ticker symbol of ClearPoint Neuro Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ClearPoint Neuro Inc (CLPT)?

As of Thu May 02 2024, market cap of ClearPoint Neuro Inc is 148.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLPT stock?

You can check CLPT's fair value in chart for subscribers.

What is the fair value of CLPT stock?

You can check CLPT's fair value in chart for subscribers. The fair value of ClearPoint Neuro Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ClearPoint Neuro Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ClearPoint Neuro Inc a good stock to buy?

The fair value guage provides a quick view whether CLPT is over valued or under valued. Whether ClearPoint Neuro Inc is cheap or expensive depends on the assumptions which impact ClearPoint Neuro Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLPT.

What is ClearPoint Neuro Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, CLPT's PE ratio (Price to Earnings) is -6.74 and Price to Sales (PS) ratio is 6.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ClearPoint Neuro Inc's stock?

In the past 10 years, ClearPoint Neuro Inc has provided 0.179 (multiply by 100 for percentage) rate of return.